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Abstract 
DC-SIGN is a C-type lectin receptor on antigen presenting cells (dendritic cells) which has an 
important role in some viral infection, notably by HIV and Dengue virus (DV). Multivalent 
presentation of carbohydrates on dendrimeric scaffolds has been shown to inhibit DC-SIGN binding 
to HIV envelope glycoprotein gp120, thus blocking viral entry. This approach has interesting 
potential applications for infection prophylaxis. In an effort to develop high affinity inhibitors of 
DC-SIGN mediated viral entry, we have synthesized a group of glycodendrimers of different 
valency that bear different carbohydrates or glycomimetic DC-SIGN ligands and have studied their 
DC-SIGN binding activity and antiviral properties both in an HIV and a Dengue infection model. 
Surface Plasmon Resonance (SPR) competition studies have demonstrated that the materials 
obtained bind efficiently to DC-SIGN with IC50s in the M range, which depend on the nature of 
the ligand and on the valency of the scaffold. In particular, a hexavalent presentation of the DC-
SIGN selective antagonist 4 displayed high potency, as well as improved accessibility and chemical 
stability relative to previously reported dendrimers. At low M concentration the material was 
shown to block both DC-SIGN mediated uptake of DV by Raji cells and HIV trans-infection of T-
cells. 
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Introduction 
Cells of the innate immune system use pattern recognition receptors (PRRs) to identify 
pathogen-associated molecular patterns. The two major families of membrane-bound PRRs found in 
sentinel cells, as macrophages and dendritic cells, are Toll-like receptors (TLRs) and C-type lectin 
receptors (CLRs). DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing 
Nonintegrin) is a CLR used by immature dendritic cells (DCs) in mucosal tissue to recognize high-
mannose glycans present on the surface of invading microorganisms. For some pathogens, 
including viruses like HIV, Ebola or Dengue,[1] this recognition event contributes to infection by 
promoting viral transmission, rather than protecting the host. This observation has turned DC-SIGN 
into an interesting target for the design of anti-viral agents.[2-10] The task is complicated by the 
presence of other C-type lectins of similar selectivity, like Langerin,[11] that has a protective effect 
against HIV infection. Thus, selective DC-SIGN ligands that interact only weakly with Langerin are 
actively sought after as potentially useful therapeutic tools against HIV and other viruses that use 
DC-SIGN as a primary receptor.[12-15]  
DC-SIGN is a tetramer and is organized into clustered patches at the cell membrane.[16, 17] 
Interactions with pathogens, also expressing multiple copies of clustered glycans, involve a 
complex equilibrium that implies multipoint attachments. For this reason the principle of 
multivalency has been used with success in the development of antagonists of DC-SIGN and 
numerous reports have appeared in the literature concerning mannosylated dendrimers or polymers 
that target it.[8, 10, 18-22]  Multivalent structures bearing sugar mimics were previously prepared 
in our group[10, 18] using Boltorn type dendrimers and dendrons derived from 2,2-
bis(hydroxymethyl) propionic acid. These scaffolds have a polyester backbone of good flexibility 
and water solubility, and their outer layers are functionalized with carboxylic groups. Ligand 
conjugation occurs via amide bond formation with amine functionalities on the monovalent ligands. 
In particular, the tetravalent pseudo-trimannoside 1.2 (Figure 1), bearing four copies of the 
trimannoside mimic 2a, was found to interact selectively with DC-SIGN versus Langerin and block 
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HIV-1 infection both in cellular and human cervical explant models.[12, 13] Further analysis of 
multivalent constructs bearing up to 30-32 copies of trimannoside mimic 2a or the corresponding 
pseudo-disaccharide 3a[18] provided nanomolar inhibitors of an Ebola pseudotyped virus infection, 
but showed some drawbacks, such as relatively long synthesis and chemical instability of the 
scaffolds. Additionally, these studies revealed that the pseudo-disaccharide 3, once presented on a 
polyvalent construct, is only marginally less active as a DC-SIGN antagonist than the more 
synthetically complex pseudo-trisaccharide 2. Further campaigns, directed to optimization of the 
pseudo-disaccharide structure, led to a new lead, the bis-benzylamide 4, which binds DC-SIGN 
with an affinity approaching that measured for 2, while displaying improved selectivity.[15]  
In the development of this research, we have sought to exploit antagonist 4 as the active element of 
new glycodendrimers. To overcome the problems met with Boltorn-type structures, a set of 
polyalkynes were planned as dendrimer cores, in order to take advantage of Cu(I) catalyzed azide-
alkyne cycloaddition (CuAAC, click chemistry) of 4. This approach has the potential to afford 
multivalent DC-SIGN antagonists of high potency, that also display improved accessibility and 
chemical stability over previously studied materials. Their DC-SIGN binding properties could be 
studied in Surface Plasmon Resonance (SPR) and in infection cellular models, using azido-
functionalized mannose 5[23], the pseudo-trisaccharide 2b[24] and pseudo-disaccharide 3b[25]  to 
synthesize appropriate controls.  
 
2. Materials and methods  
2.1 Synthesis  
2.1.1 General  
Dichloromethane, methanol, N,N-diisopropylethylamine and triethylamine were dried over calcium 
hydride; THF was distilled over sodium, N,N-dimethylacetamide (DMA) was dried over activated 
molecular sieves (4 Å). Reactions requiring anhydrous conditions were performed under nitrogen. 
1H and 13C spectra were recorded at 500 MHz on a Bruker DRX 500, 400 MHz on a Bruker 
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AVANCE-400 and 300 MHz on Bruker DPX-300 instrument. Chemical shifts (δ) for 1H and 13C 
spectra are expressed in ppm relative to internal standard (CDCl3: 7.24 for 1H and 77.23 for 13C; 
CD3OD: 3.31 for 1H and 49.15 for 13C; D2O: 4.80 for 1H; DMSO-D6: 2.50 for 1H and 39.52 for 
13C). Signals were abbreviated as s, singlet; br s, broad singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet. Mass spectra were obtained with a ThermoFisher LCQ apparatus (ESI ionization), or 
iontrap ESI Esquire 6000 from Bruker, or a Microflex apparatus (MALDI ionization) from Bruker, 
or Apex II ICR FTMS (ESI ionization-HRMS). Specific optical rotation values were measured 
using a Perkin-Elmer 241, at 589 nm, in a 1 dm cell. Thin layer chromatography (TLC) was carried 
out with pre-coated Merck F254 silica gel plates. Flash chromatography (FC) was carried out with 
Macherey-Nagel silica gel 60 (230–400 mesh). 
Compounds 3, [25] 4, [15] 7, [26] 9, [27] 11, [28] and 14[29] have been previously described. The 
tetravalent mannosylated dendrimer 11.5 is a known compound.[28] The synthesis and 
characterization of materials derived from monovalent ligand 4 (11.4, 13.4 and 9.15.4) is described 
below.  The synthesis and characterization of all other glycodendrimers are reported in the 
Supplementary Information file. 
The numbering used in the NMR characterizations is indicated in the structures reported in the 
Supplementary Information file (Figure SI-9). Sugar signals were numbered as customary; 
cyclohexane protons are indicated with the letter D followed by numbers. The unusual numbering 
of the pseudo-saccharide derivatives in the NMR characterizations was adopted to facilitate 
comparison with the native disaccharide 
2.1.2 General procedure for the CuAAC reaction (click reactions) 
In the optimized procedure of the copper(I) catalyzed 1,3-dipolar cycloaddition, the starting 
materials and reagents were added to the reaction mixtures as solutions in water (degased by 
bubbling with nitrogen) or THF (freshly distilled). Monovalent ligands (2-4) and dendrons (15.3 
and 15.4) with azide groups were added as solids. The reagents were added to the reaction in the 
following order: multivalent scaffold (1 eq. in THF), TBTA (1 eq. in THF), copper(II) sulphate 
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(0.1 eq. in H2O), sodium ascorbate (0.4 eq. in H2O) and finally the azide derivative (1.1 eq. per 
alkyne). After the addition of all the reagents, the solvent ratio was adjusted to 1:1 by addition of 
THF and/or water (c =  0.03 M). The reactions were stirred under nitrogen atmosphere, and 
protected from light. The reaction progress was followed by TLC (silica, Hex:EtOAc = 8:2 and 
C18, H2O: MeOH = 1:1) or mass spectrometry (MALDI or ESI ionization). Usually, in order to 
achieve reaction completion, an additional 0.4 eq. of sodium ascorbate was added (2-4 h after 
reaction start). After reaction completion the mixtures were loaded directly on SEPHADEX LH-20 
columns (55 cm x 3.5 cm, MeOH as eluent) to purify the products by size exclusion 
chromatography. In order to remove copper residues from the products, reverse phase 
chromatography was performed (C18, eluent: H2O with gradients of MeOH or MeCN) or to the 
solution of product in MeOH a metal scavenger[30] (such as QuadrasilTM MP) was added and 
stirred for 5 min. The scavenger was filtered off through a cotton pad and the filtrate was 
concentrated to obtain the product. 
2.1.3 Synthesis of hexa(2-propynyloxymethyl) bispentaerythritol, 13 
To a solution of bispentaerythritol (0.3 g, 1.18 mmol, 1 eq.) in dry DMF (20 mL), sodium hydride 
(0.34 g, 14 mmol, 11.8 eq.) was added under argon at -5ºC. The solution was stirred at -5ºC for 1 h 
then propargyl bromide (1.15 mL, 14 mmol, 11.8 eq.) was added and the mixture was kept at -5ºC 
for additional 20 min. The reaction was let to warm up to room temperature and stirred for 19 h. 
The reaction was cooled to 0ºC, quenched by slow addition of water and extracted with diethyl 
ether (3 x 30 mL). The combined organic phases were dried over sodium sulphate and concentrated 
under reduced pressure. The crude was purified by flash chromatography (silica, hex:Ethyl Acetate 
= 9:1 and 8.5:1.5) to afford 130 mg of pure product. Yield: 65%; MS (HRMS) calculated for 
[C28H34O7Na]+: 483.2383; found = 483.2379; 1H NMR (300 MHz, CDCl3): δ = 4.12 (d, 12H, H3, 
J3-1 = 2.4 Hz), 3.52 (s, 12H, H4), 3.38 (s, 4H, H6), 2.53 (t, 6H, H1, J3-1 = 2.4 Hz); 13C NMR 
(75 MHz, CDCl3): δ = δ 80.2 (C1); 74.3 (C2); 69.9 (C3); 69.3 (C4); 58.9 (C6); 45.2 (C5). 
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2.1.4 Synthesis of tetravalent glycodendrimer 11.4 
Prepared according to the general procedure starting from 11[28] and 4[15]. Reaction time: 18 h; 
Yield: 87%; [α]D 25 = - 4.7 (c = 0.21, MeOH); MS (MALDI, matrix: -cyano-4-hydroxy-
cinnamic acid, solvent: MeOH): calculated for [C145H192N20O48Na]+: 3006.2; found = 3005.4; MS 
(ESI-HRMS): calculated for [C145H192N20O48]+: 2981.3198; found = 2981.3244 (after 
deconvolution, error: 1.6 ppm); 1H NMR (400 MHz, CD3OD): δ = 7.96 (s, 4H, H16), 7.31 – 7.07 
(m, 32H, H12, H13), 4.89 (br s, 4H, H1), 4.54 (s, 16H, H15), 4.51 (t, 8H, H8, J8-7 = 5.4 Hz), 4.44 (s, 
8H, H18), 4.27 (s, 8H, H10a), 4.25 (s, 8H, H10b), 3.95 - 3.80 (m, 20H, H2, H6a, D2, H7), 3.72 - 3.60 (m, 
12H, H6b, D1, H3), 3.59 - 3.49 (m, 8H, H4, H5), 3.44 (br s, 8H, H19), 2.90 – 2.75 (m, 8H, D4, D5), 
1.96 – 1.66 (m, 16H, D3, D6); 13C NMR (100 MHz, CD3OD): δ = 177.1, 176.9 (C9); 146.3 (C17); 
141.7 (C14); 139.2 (C11); 128.5, 128.3 (C13, C12); 126.2 (C16); 100.6 (C1); 76.3 (C3); 75.7 (CD1); 72.7 
(D2); 72.5 (C2); 72.4 (C5); 70.0 (C19); 69.0 (C4); 68.5 (C7); 65.5 (C18); 65.1 (C15); 63.3 (C6); 52.6 
(C10); 51.7 (C8); 46.7 (C20); 43.8 (C10); 41.9, 41.9 (CD4, CD5); 29.9, 29.2 (CD3, CD6).  
2.1.5 Synthesis of hexavalent glycodendrimer 13.4 
Prepared according to the general procedure starting from 13 and 4[15]. Reaction time: 18 h; 
Yield: 70%; [α]D 25 = - 2.8 (c = 0.27, MeOH); MS (MALDI, matrix: 2,5-dihydroxybenzoic acid, 
solvent: MeOH); calculated for [C220H292N30O73]+: 4524.8; found = 4524.7 [M]+ and 
4549.1[M+Na]+; MS (ESI-HRMS): calculated for [C220H292N30O73]+: 4522.0059; found = 
4522.0147 (after deconvolution, error: 2.0 ppm); 1H NMR (400 MHz, CD3OD): δ = 7.95 (s, 6H, 
H16), 7.28 – 7.07 (m, 48H, H12, H13), 4.89 ( br s, 6H, H1), 4.54 (s, 24H, H15), 4.51 - 4.45 (m, 12H, 
H8), 4.44 (s, 12H, H18), 4.28 - 4.20 (m, 24H, H10), 3.95 - 3.80 (m, 30H, H2, H6a, D2, H7), 3.73 - 3.61 
(m, 18H, H6b, D1, H3), 3.60 - 3.47 (m, 12H, H4, H5), 3.38 (br s, 12H, H19), 3.26 (br s, 4H, H21), 2.89 
– 2.78 (m, 12H, D4, D5), 1.93 – 1.69 (m, 24H, D3, D6); 13C NMR (100 MHz, CD3OD): δ = 177.1, 
176.9 (C9); 146.3 (C17); 141.7 (C14); 139.2 (C11); 128.6, 128.3 (C13, C12); 126.1 (C16); 100.7 (C1); 
76.3 (C3); 75.7 (CD1); 72.7 (D2); 72.5 (C2, C5); 71.1 (C21); 70.3 (C19); 69.0 (C4); 68.5 (C7); 65.5 
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(C18); 65.1 (C15); 63.3 (C6); 52.6 (C10); 51.7 (C8); 43.8 (C10); 41.9, 41.9 (CD4, CD5); 29.9, 29.3 (CD3, 
CD6).  
2.1.6 Synthesis of trivalent glycodendron 15.4 
Dendron 14.4 was initially prepared, according to the general procedure and starting from 14[29] 
and 4[15]. Reaction time: 3 h; Yield: 81%; MS (MALDI matrix: sinapinic acid, solvent: 
MeOH): calculated for [C114H154ClN15O38]+: 2378.0; found = 2378.5; 1H NMR (400 MHz, 
CD3OD): δ = 7.98 (s, 3H, H16); 7.28 – 7.16 (m, 24H, H12, H13); 4.89 (br s, 3H, H1); 4.58 – 4.50 (m, 
6H, H8); 4.55 (s, 12H, H15); 4.48 (s, 6H, H18); 4.28 (s, 6H, H10); 4.26 (s, 6H, H10); 3.99 - 3.80 (m, 
15H, H2, H6a, D2, H7); 3.73 - 3.61 (m, 11H, H6b, D1, H3, H25); 3.61 - 3.44 (m, 12H, H4, H5, H22, H23, 
H24), 3.42 (br s, 6H, H19), 3.39 (br s, 2H, H21), 2.90 – 2.76 (m, 6H, D4, D5), 1.96 – 1.68 (m, 12H, D3, 
D6); 13C NMR (100 MHz, CD3OD): δ = 177.1, 176.9 (C9), 146.3 (C17), 141.7 (C14), 139.2 (C11), 
128.5, 128.3 (C13, C12), 126.2 (C16), 100.5 (C1), 76.3 (C3); 75.7 (CD1); 72.7 (D2); 72.6 (C24); 72.5, 
72.4 (C2, C5); 72.2, 71.5 (C22, C23); 70.9 (C21); 70.2 (C19); 69.0 (C4); 68.5 (C7); 65.5 (C18); 65.1 
(C15); 63.3 (C6); 51.7 (C8); 46.7 (C20); 44.2 (C25); 43.8 (C10); 41.9, 41.9 (CD4, CD5); 29.9, 29.3 (CD3, 
CD6).  
To a solution of 14.4 (150 mg, 0.0631 mmol, 1 eq.) in DMF (1 mL) sodium azide (25 mg, 
0.378 mmol, 6 eq.) was added. The reaction was stirred at 65ºC for 4 days. The solvent was 
removed under reduced pressure and the resulting crude was purified by reverse phase flash 
chromatography (C18, water with gradient of MeOH from 0% to 70%) to afford 143 mg of pure 
product. Yield: 95%; MS (MALDI matrix: sinapinic acid, solvent: MeOH): calculated for 
[C114H154N18O38]+: 2384,5; found = 2385.3; 1H NMR (400 MHz, CD3OD): δ = 7.98 (s, 3H, H16), 
7.30 – 7.13 (m, 24H, H12, H13), 4.89 (br s, 3H, H1), 4.60 – 4.50 (m, 6H, H8), 4.55 (s, 12H, H15), 4.48 
(s, 6H, H18), 4.28 (s, 6H, H10), 4.26 (s, 6H, H10), 3.97 - 3.80 (m, 15H, H2, H6a, D2, H7), 3.73 - 3.62 
(m, 9H, H6b, D1, H3), 3.62 - 3.46 (m, 14H, H4, H5, H22, H23, H24, H25), 3.43 (br s, 6H, H19), 3.40 
(br s, 2H, H21), 2.90 – 2.76 (m, 6H, D4, D5), 1.96 – 1.69 (m, 12H, D3, D6).; 13C NMR (100 MHz, 
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CD3OD): δ = 177.1, 176.8 (C9), 146.3 (C17), 141.7 (C14), 139.2 (C11), 128.5, 128.3 (C13, C12), 126.2 
(C16), 100.5 (C1), 76.3 (C3); 75.7 (CD1); 72.7 (D2); 72.5, 72.4  (C2, C5); 72.3, 71.5, 71.3 (C22, C23, 
C24); 70.9 (C21); 70.2 (C19); 69.0 (C4); 68.5 (C7); 65.5 (C18); 65.1 (C15); 63.2 (C6); 51.9 (C25); 51.7 
(C8); 46.7 (C20); 43.8 (C10); 41.9, 41.8 (CD4, CD5); 29.9, 29.2 (CD3, CD6).  
2.1.7 Synthesis of nonavalent glycodendrimer 9.15.4 
Prepared according to the general procedure starting from 9[27] and 15.4. Reaction time: 18 h; 
Yield: 75%; MS (MALDI, matrix: sinapinic acid, solvent: MeOH): calculated for 
[C357H474N54O117]+: 7393,9; found = 7394.5; MS (ESI-HRMS): calculated for [C357H474N54O117]+: 
7389.2801; found = 7393.2866 (after deconvolution, error: 0.7 ppm); 1H NMR (400 MHz, 
CD3OD): δ = 8.05 (s, 3H, H26), 7.95 (s, 9H, H16), 7.28 – 7.11 (m, 72H, H12, H13), 6.29 (br s, 3H, 
H30), 5.03 (br s, 6H, H28), 4.89 (br s, 9H, H1), 4.63 (s, 6H, H25), 4.55 (s, 36H, H15), 4.52 – 4.46 (m, 
18H, H8), 4.45 (s, 12H, H18), 4.27 (s, 18H, H10), 4.25 (s, 18H, H10), 3.96 - 3.75 (m, 51H, H2, H6a, 
D2, H7, H24), 3.75 - 3.62 (m, 27H, H6b, D1, H3), 3.61 - 3.42 (m, 30H, H4, H5, H22, H23), 3.39 (br s, 
18H, H19), 3.36 (br s, 6H, H21), 2.89 – 2.81 (m, 18H, D4, D5), 1.96 – 1.68 (m, 36H, D3, D6). 
1H NMR (400 MHz, DMSO-D6): δ = 8.31 (t, 9H, HNH, J10-NH = 5.3 Hz), 8.31 (t, 9H, HNH, J10-NH = 
5.3 Hz), 8.17 (s, 3H, H26), 8.01 (s, 9H, H16), 7.24 – 7.07 (m, 72H, H12, H13), 6.33 (br s, 3H, H30), 
5.09 (t, 18H, HOH-C15, JH15-OH = 5.6 Hz), 5.05 (br s, 6H, H28), 4.76 (br s, 9H, H1), 4.74 (d, 9H, HOH-
C3, JH3-OH = 4.6 Hz), 4.67 (d, 9H, HOH-C2, JH2-OH = 3.9 Hz), 4.59 (d, 9H, HOH-C4, JH4-OH = 5.5 Hz), 
4.54 – 4.46 (m, 27H, H8, HOH-C4), 4.46 - 4.37 (m, 54H, H15, H18), 4.17 (br s, 36H, H10), 3.93 - 3.85 
(m, 9H, H7a), 3.83 – 3.72 (m, 18H, D2, H7b), 3.72 – 3.62 (m, 18H, H2, H6a), 3.60 (br s, 9H, D1), 3.52 
- 3.20 (m, 84H, H3, H4, H5, H6b, H19, H21, H22, H23, H24, H25), 2.81 – 2.63 (m, 18H, D4, D5), 1.83 – 
1.46 (m, 36H, D3, D6).13C NMR (100 MHz, DMSO-D6): δ = 174.1, 174.0 (C9); 144.0 (C29); 140.7 
(C14); 138.0 (C11); 126.7, 126.6, 126.3 (C12 ,C13); 124.9 (C26); 124.2 (C16); 98.8 (C1); 94.5 (C30); 
74.6 (C5); 74.2 (CD1); 70.9 (C3); 70.5 (C2); 70.4 (D2); 69.1 (C21); 68.7 (C19); 67.1 (C7); 67 - 63 (C22, 
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C23, C24); 62.7 (C15, C18); 61.3 (C28, C6); 49.4 (C8); 44.9 (C25); 41.6 (C10); 39.3 (CD4, CD5); 28.2, 27.9 
(CD3, CD6).  
2.2 SPR methods. 
SPR competition experiments were performed on a Biacore 3000 instrument. Flow cells (Fc) 2 and 
1 of sensor chip CM4 were functionalized with mannosylated bovine serum albumine (Man α1-
3[Manα1-6]Man BSA (Man-BSA), Dextra Laboratories) or prepared as control surface, 
respectively, as described previously[15]. The final response of immobilized Man-BSA was 5000 
RU. 
The competition experiment was performed using 25 mM Tris-HCl pH 8, 150 mM NaCl, 4 mM 
CaCl2, 0.005% P20 as the running buffer at 5 μL/min flow rate. The binding of soluble tetrameric 
DC-SIGN ECD [31]to immobilized Man-BSA was inhibited by the compounds at increasing 
concentrations (0.14 μM – 900 μM for multivalent compounds, and 0.69 μM – 4.5 mM for 
monovalent ligands). For this reason, 13 L of each DC-SIGN ECD (24 μM)/compound mixture 
was injected over the surfaces. The bound lectin was washed off by a 1 min injection of 50 mM 
EDTA pH 8. DC-SIGN ECD equilibrium binding responses (Req) for each sample were obtained 
from the reference surface corrected sensorgrams 150 s after the start of the injection. 
    (1) 
    (2)
 
where Rhi and Rlo are maximum and minimum asymptotes, A1 is an inflection point and A2 is a slope 
of the curve. 
The obtained Req values were converted to DC-SIGN residual activity values (y, %) with respect to 
Req of DC-SIGN alone, which was assigned a 100% activity value. After plotting residual activity 
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against corresponding compound concentration, the 4-parameter logistic model (eq, 1) was fitted to 
the plots, and finally the IC50 values were calculated using equation 2. 
2.3 Infection studies methods  
2.3.1 HIV infection studies.  
For HIV studies, B-THP-1/DC-SIGN cells, that support DC-SIGN mediated HIV-1 transmission 
efficiently, were exploited as a model of DCs. Non-transfected B-THP-1 cells were used as a 
negative control. B-THP-1/DC-SIGN cells[32] or B-THP-1 cells were pre-incubated for 30 minutes 
in the presence or absence of the DC-SIGN inhibitors and afterwards were pulsed with HIV (the R5 
tropic laboratory-adapted strain HIV-1 BaL) in the continued presence of inhibitors. After washing, 
B-THP-1/DC-SIGN cells were co-cultured with activated CD4+ T lymphocytes from healthy 
volunteer donors. To monitor viral infection of CD4+ T lymphocytes, HIV-1 p24 concentration in 
the co-culture supernatants was assessed by ELISA. Each point was obtained in triplicate using 
CD4+ T lymphocytes derived from three different healthy donors, and each compound was tested at 
three different concentrations (1 µM, 10 µM and 100 µM). Details are given in the Supplementary 
information.  
2.3.2 DV infection studies.  
Raji cells over-expressing DC-SIGN were infected with Dengue virus serotype-2 in the presence or 
absence of 13.4 at three different concentrations (10 M, 5 M and 1 M). The infection was 
scored after 48 hours at 37°C, using DV prM protein specific antibody 2H2. Mannan at 250 μg/mL 
was used as positive control for infection inhibition. 
2.3.3 Cyotoxicity studies  
To assess the potential cytotoxicity of the glycodendrimers tested in cellular models (11.3, 11.4, and 
13.4), B-THP-1/DC-SIGN cells or pheripheral blood mononuclear cells (PBMCs) were incubated 
for the indicated time intervals with different concentrations of the compounds (1 µM, 10 µM, and 
100 µM), followed by staining with 7-aminoactinomicin D (7-AAD), that penetrates cell membrane 
of dying or dead cells. Percentage of 7-AAD positive cells (non-viable cells) did not change 
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significantly in the absence of the compounds or in their presence up to 100 µM, the highest 
concentration assayed in the cellular infection models (Supplementary Figures SI-4 and SI-5). 
The cytotoxicity of 13.4 towards Raji-DC-SIGN cells was also assessed using the MTT test (Figure 
SI-6, MTT cytotoxicity testing kit from Sigma). The experiment was performed according to 
manufacturer’s instructions. Different concentrations of 13.4 were tested on Raji-DC-SIGN cells 
and percentage of live cells was directly proportional to the absorbance detected by 
spectrophotometer. The absorbance values were expressed as relative percentage compared to mock 
cells. Equal amount of DMSO was used as control. The results indicate that 13.4 is not cytotoxic to 
cells at the concentrations used in the infection assays. 
 
3. Results and discussion. 
3.1 Synthesis  and characterization of the glycodendrimers 
The divalent alkyne 7[26] was prepared from ditosylate 6 by reaction with an excess of propargyl 
alcohol in the presence of potassium carbonate (Scheme 1). Compounds 9, [27] 11, [27] and 13 
were prepared in one step from commercially available starting materials. The general strategy is 
based on treating polyalcohols 8, 10 or 12 with an appropriate base in the presence of propargyl 
bromide (Scheme 1). The basic structures 7, 9, 11, 13 can lead to di-, tri-, tetra- and hexa-valent 
presentations of a monovalent ligand, respectively. Additionally, the known trivalent dendron 14 
[29] was prepared from 10 (Scheme 1). Dendron 14 can be functionalized by Cu(I) catalyzed azide-
alkyne cycloaddition (CuAAC) with three copies of a ligand and, after transformation of the 
chloride tethered to the focal point into an azide (yielding 15, Figure 2), it can be clicked on other 
polyalkynes such as 7, 9, 11, 13, leading to compounds with higher valency and different shapes 
(Figure 2).  
With this approach the 17 polyvalent constructs shown in Figure 2 were synthesized by CuAAC 
with ligands 2b, 3b, 4-5. Among them, one tetravalent (11.4), one hexavalent (13.4) and one 
nonavalent (9.15.4) dendrimers bear the lead mimic 4 (Figure 2). Controls with valency up to 18 
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were built using mannose 5, the pseudo-dimannoside 3 and the pseudo-trimannoside 2 as the 
monovalent ligand (see Supplementary Information). The dendrimers were isolated from the 
reaction mixtures by size exclusion chromatography on Sephadex LH20 matrix using MeOH as 
eluent. Residual copper was removed either by reverse phase chromatography (C18) or using metal 
scavengers (Quadrasil MP)[30]. All materials were found to be stable for months in water solution 
and were fully characterized by MALDI-MS analysis (sinapinic acid or DBA) and by 1H and 13C-
NMR spectroscopy.  
3.2 Surface Plasmon Resonance studies 
All the glycodendrimers were tested by SPR, using a protocol that we have previously 
described.[33] The assay allows to compare the relative affinity of ligands on the basis of their 
ability to inhibit DC-SIGN binding to mannosylated bovine serum albumin (Man-BSA) 
immobilized onto a carboxymethyl dextran- functionalized gold SPR sensor chip (CM4). Inhibition 
studies were performed using the extracellular domain (ECD) of DC- SIGN (24 µM) injected alone 
or in the presence of increasing concentrations of ligands. The 50% inhibition concentration (IC50) 
of the dendrimers was determined and the values were compared to those obtained with the 
previously described tetravalent Boltorn-type dendrons 1.  
Figure 3 shows the results of a first series of experiments focused on materials derived from the 
pseudo-disaccharide 3. This set of experiments revealed that the pentaerythritol based dendrimers 
compare well with the previously studied Boltorn-type ones. Indeed, the two tetravalent 
presentations 1.3 and 11.3 display basically the same activity and the same relative inhibitory 
potency (RIP) per ligand unit (ca. 1.5) compared to the monovalent counterpart 3. The two 
hexavalent ligands 13.3 and 7.15.3 showed approximately the same potency with IC50 = 37 µM and 
33 µM, respectively. This suggests that, unlike the valency, the shape of the multivalent molecule 
may have a minor influence on the activity, at least in this type of assay. On the other hand, the 
PEG core of 7.15.3 may just be too flexible to modify the 3D structure of the dendrimer in a 
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significant way. The most remarkable improvement was observed in the case of the nonavalent 
system 9.15.3, which, with a 15 µM IC50, displays a RIP of 8.  
The SPR competition assay results for all compounds of Figure 2 are shown in Figure 4 and the 
corresponding IC50 values are listed in Table 1. A gradual increase of activity was observed as a 
function of the scaffold valence increment for all ligands, except those derived from the 
pseudotrisaccharide 2, that show RIP < 1 (Table 1, column 3). This unusual behavior of polyvalent 
materials derived form 2 was already observed for polyester dendrons[18] and is now confirmed to 
occur independently of the nature of the polyvalent support. More structural experiments are being 
carried out in our laboratory to analyze the factors that govern this phenomenon. Tethering mannose 
on tetravalent and hexavalent scaffolds afforded very minor improvements, but the affinity 
gradually increased with higher valence dendrimers, reaching an IC50 = 36 µM for the 18-valent 
construct 13.15.5 (RIP 5; Table 1, Entry 7, Man column). Comparing the activities of materials with 
different ligands, it is obvious that the selected lead 4 gives the best activity in the group. The 
tetravalent and hexavalent constructs 11.4 and 13.4 displayed a RIP of 6 and 9, respectively, leading 
to an IC50 = 6 µM for 13.4 (Table 1, Entry 3, column 4). The threshold for water solubility of the 
nonavalent construct 9.15.4 was found to be at ca. 2 mg/mL (0.3 µM), which prevented the 
determination of activity curves. Nonetheless, the advantage of using a more powerful monovalent 
ligand in the preparation of multivalent constructs is obviously shown from these data (Figure 4): 
IC50 values in the low micromolar range are rapidly reached using the most powerful ligand 4 even 
in tetravalent presentation. Other mannosylated and pseudo-mannosylated materials lag behind, 
even when the sugar is presented with higher valency on the dendrimers. 
3.3 MD simulations of dendrimers 11 and 13 
In order to interpret the multivalency effect observed for the materials under study, it must be kept 
in mind that the SPR competition assay used here measures the ability of the dendrimers to inhibit 
binding of soluble DC-SIGN tetramers to an immobilized binding partner. Under these conditions, 
various effects can be operative. In principle, they may include 1) a high local concentration of the 
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ligand exposed by the dendrimers (or high effective molarity, which favors statistical rebinding;[34] 
2) chelation, i.e. simultaneous binding of multiple binding sites by a single dendrimer on a single 
DC-SIGN tetramer, or 3) the ability of the dendrimers to cluster soluble DC-SIGN tetramers. [22]  
To gauge the average dimension of the most active dendrimers 11.4  and 13.4 and to estimate 
whether they can effectively span the distance between two DC-SIGN Ca2+ binding sites which are 
separated by approximately 4 nm, molecular dynamics simulations were employed. To speed up the 
calculations, the simulations were performed on models 11.3  and 13.3, that ought to have the same 
size of the materials derived from 4. Since mannose binds to DC-SIGN Ca2+ ions using O3 and O4, 
the distances between these atoms in different Man residues were monitored continuously during 
the dynamics, that were run for a total of 60 ns (details for 11.3 are collected in the Supplementary 
Information section). Results showed that, even at maximum extension, the distance between the 
two farthest Man-O3 is well below 4 nm (30.6 Å for 11.3 and 35.4 Å for 13.3, Figure 5), so that 
chelation of two sites on the same DC-SIGN tetramer cannot be achieved. Hence, it is most likely 
that the modest multivalency effects measured for 11.4 and 13.4 result from increased effective 
molarity of the ligands and/or from an ability to cluster the soluble tetramers in the SPR 
experiments. In the real biological settings, where DC-SIGN is exposed on the surface of (dendritic) 
cells, this latter effect may be lost, or it may be translated into an ability to promote receptor 
clustering at the cell surface. Thus it is of interest to explore the activity of the dendrimers described 
here in cellular models of viral infections. 
3.4 Infection tests  
Tests were performed on both an HIV infection and a Dengue virus (DV) infection models.  
DC-SIGN promotes HIV transmission by DCs to CD4+ T cells (infection in trans)[35]. For HIV 
studies, B-THP-1/DC-SIGN cells, that support DC-SIGN mediated HIV-1 transmission efficiently, 
were exploited as a model of DCs. The cells were pre-incubated for 30 minutes in the presence or 
absence of the DC-SIGN inhibitors and afterwards were pulsed with HIV-1 BaL in the continued 
presence of inhibitors. After washing, the B-THP-1/DC-SIGN cells were co-cultured with activated 
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CD4+ T lymphocytes from healthy volunteer donors. Viral infection of CD4+ T lymphocytes was 
monitored quantifying the concentration of the HIV-1 core protein p24 in the co-culture 
supernatants by ELISA. Mannan, a known DC-SIGN inhibitor[35-37] was used as a positive 
control. Non-transfected B-THP-1 cells, as expected, did not transmit infection. The HIV trans 
infection studies focused on those multivalent structures which were found to be the most active in 
the SPR experiment, namely dendrimers 11.4 and 13.4, bearing 4 and 6 copies of the bisamide 4. 
The results were compared to those obtained with 11.3 (tetravalent presentation of the pseudo-
disaccharide 3) to examine the effect of the monovalent ligand, and with the previously described 
tetravalent Boltorn-type dendron 1.2.  [1, 2](Figure 6 and Supplementary Figure SI-3). 
Tetravalent 11.3 reduced the infection to 66% and 26% at 10 µM and 100 µM concentrations, 
respectively. After treatment with compound 11.4, bearing four copies of 4, 47% of infection was 
determined at 10 µM and almost no infection took place at 100 µM concentration. The most 
impressive inhibition of HIV trans infection was observed in the case of 13.4 (hexavalent 4). At 
1 µM concentration the infection was reduced to 50%, and at 10 µM and 100 µM the infection was 
completely suppressed. For comparison, the previously known tetravalent Boltorn-type pseudo-
trisaccharide 1.2 showed similar activity to 11.4 (no infection at 100 µM) and was therefore clearly 
outperformed by 13.4, which reduced the infection to 0% at 10-fold lower concentrations. 
DC-SIGN also plays an important role during the transmission of Dengue virus and is considered as 
a target for therapeutics that block Dengue infection.[38, 39] Dengue infection is primarily 
transmitted by mosquitoes and the symptoms include fever, muscle and joint pains and skin rash. 
Methods for the control and prevention of Dengue by vaccination have not been established, yet 
[40]and previous attempts in our groups to block DC-SIGN mediated DV infections using  
mannosylated materials based on Boltorn scaffolds were unsuccessful. In order to examine the 
potential activity of the glycodendrimers to inhibit Dengue virus infection, Raji cells over-
expressing DC-SIGN were infected with Dengue virus serotype-2 in the presence or absence of 
13.4 at different concentrations, 10 M, 5 M and 1 M (Figure 7). Gratifyingly, dendrimer 13.4 
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showed concentration-dependent antiviral activity. At 10 µM concentration the infection was 
inhibited by about 85% and the IC50 was found to be 5.9 µM. The effect of 13.4 lasted even when 
the compound was removed 30 minutes after infection (Supplementary Information, Figure SI-7). 
3.5 Discussion 
A majority of pathogens that infect humans use the mucosal entry pathway. These pathogens 
include respiratory viruses and those responsible for sexually transmitted diseases including HIV 
and Human Papilloma Virus (HPV). Notably, mucosal infections continue to represent a challenge 
for the development of either preventive or therapeutic vaccines. A number of mucosal pathogens 
recognize DC-SIGN as their primary target. Therefore, the design of materials capable of 
interacting efficiently with DC-SIGN and of blocking the infections by pathogens that use this 
lectin to access the target cells is a topic of tremendous interest. Towards this goal, we have 
developed a strategy based on a very efficient click chemistry approach that allows to conjugate 
different carbohydrate and glycomimetic ligands to a variety of multimeric scaffolds with different 
valency. SPR competition studies have demonstrated that the dendrimers obtained bind efficiently 
to DC-SIGN with IC50s in the M range. 
Among the materials synthesized, those based on the monovalent ligand 4 are the most interesting 
ones, since this ligand possesses the best selectivity observed to date for DC-SIGN versus Langerin, 
a critical issue for inhibiting HIV infection. These materials were also found to be the most active 
ones in the present study. The results showed that multivalent ligands functionalized with 4 can 
inhibit both HIV and Dengue virus at low micromolar range. In particular, the hexavalent dendrimer 
13.4 exhibits a low M range activity inhibiting trans-infection of T-cells by HIV in cellular studies 
and provides 100% inhibition of the infection at 10 M concentration. The activity shown by 13.4 
in the Dengue infection model is also very promising and it will be pursued further. Like HIV, 
Dengue virus is critically dependent on DC-SIGN for host infection. No clinical treatments are 
available for Dengue infection and there is a clear requirement for novel antiviral agents in this 
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field. Carbohydrate-based materials are under study as inhibitors of viral adsorption [40]. In our 
studies, the scaffold ligand combination provided by 13.4 is the only one that has proven effective 
to block DC-SIGN mediated uptake of DV. All previously tested dendrimers with mannose or 3 as 
a ligand were ineffective towards Dengue infection (not shown). Both the multivalent scaffold 13 
and monovalent ligand 4 can be prepared in gram scale and only one CuAAC step is required to 
obtain the functionalized dendrimer 13.4. Moreover, unlike the previously described multivalent 
compounds based on a polyester backbone, the final structure 13.4 is chemically stable. Thus 13.4 
represents a clear step forward in the quest for effective antiviral therapeutics. 
 
4. Conclusions 
In summary, we present in this work the evolution of glycomimetic ligands of DC-SIGN in 
multivalent materials synthesized using very efficient click chemistry reactions. Their relative IC50 
were determined with a SPR based test, allowing selection of compounds whose antiviral activity 
was tested using cellular models of infection with HIV and DV. The promising results obtained in 
these studies establish the bases for the preparation of improved materials with higher antiviral 
activities. Indeed, the studies performed here suggest that some improvement may still be obtained 
in avidity with scaffolds more apt to favor a chelating effect upon binding to DC-SIGN. It does not 
seem likely that such goal is already achieved with this first series of dendrimers that appear to act 
mostly through rebinding and clustering effects. 
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 Figure 1.  Monovalent glycomimetic ligands of DC-SIGN 2-5 and the tetravalent Boltorn-type dendron 1 
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Figure 2. Dendrimers synthesized in this study. 
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Figure 3. Schematic structures and IC50 values of the monovalent pseudo-disaccharide 3a, glycodendron 1.3 (Boltorn 
type) and glycodendrimers 11.3, 13.3, 7.15.3 and 9.15.3 (pentaerythritol based) measured by SPR (competition 
experiments with immobilized Man-BSA) 
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Figure 4. Comparison of the IC50 (M) values obtained for similar dendrimers with different 
monovalent ligands (2b, 3b, 4, 5) 
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Figure 5. a) Extended structure of dendrimer 11.3 and 13.3; b) Rigid docking of 11.3 (CPK model) in its extended 
structure on the DC-SIGN tetramer [31] 
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Figure 6. HIV trans infection levels after treatment with dendrimers (trans infection level measured as amount of p24 
viral protein) Experiments were performed on CD4+ T cells purified from 3 healthy donors. Data are represented as 
percentage of untreated control infection level. Values represent the mean ±SD. 
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Figure 7. Dose dependent inhibition of DV infection by 13.4. Raji-DCSIGN cells were infected with DV2 JAM at MOI-1 in 
the presence of 13.4 at different concentrations.   
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Scheme 1. Synthesis of the multivalent alkynes 7, 9, 11, 13, and 14 
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Figure captions 
 
 
 
Figure 1.  Monovalent glycomimetic ligands of DC-SIGN 2-5 and the tetravalent Boltorn-type dendron 1 
 
Figure 2. Dendrimers synthesized in this study. 
 
Figure 3. Schematic structures and IC50 values of the monovalent pseudo-disaccharide 3a, glycodendron 1.3 (Boltorn 
type) and glycodendrimers 11.3, 13.3, 7.15.3 and 9.15.3 (pentaerythritol based) measured by SPR (competition 
experiments with immobilized Man-BSA) 
 
Figure 4. Comparison of the IC50 (M) values obtained for similar dendrimers with different 
monovalent ligands (2b, 3b, 4, 5) 
 
Figure 5. a) Extended structure of dendrimer 11.3 and 13.3; b) Rigid docking of 11.3 (CPK model) in its extended 
structure on the DC-SIGN tetramer [31]  
 
Figure 6. HIV trans infection levels after treatment with dendrimers (trans infection level measured as amount of p24 
viral protein) Experiments were performed on CD4+ T cells purified from 3 healthy donors. Data are represented as 
percentage of untreated control infection level. Values represent the mean ±SD. 
 
Figure 7. Dose dependent inhibition of DV infection by 13.4. Raji-DCSIGN cells were infected with DV2 JAM at MOI-1 in 
the presence of 13.4 at different concentrations.   
 
Scheme 1. Synthesis of the multivalent alkynes 7, 9, 11, 13, and 14 
 
  
33 
 
 
Table 1. IC50 + SD values (M) obtained in DC-SIGN inhibition assays (SPR) 
    Ligand  
Entry Valency 5 
(cmpd numb., RIPa) 
2 
(cmpd numb., 
RIPa) 
3 
(cmpd numb., 
RIPa) 
4 
(cmpd numb., 
RIPa) 
1 1 3292 + 337 
(5, 1) 
145 + 83 
(2, 1) 
1018 + 109 
(3b, 1) 
308 + 40 
(4, 1) 
2 4 767 + 20 
(11.5, 1.1 ) 
112 
(11.2, 0.3) 
136 + 23 
(11.3, 1.9 ) 
12+ 3 
(11.4, 6.4 ) 
3 6 800 
(13.5, 0.7) 
51 
(13.2, 0.5) 
39 
(13.3, 4) 
5.7 + 1.6 
(13.4, 9) 
4 6 - - 32 
(7.15.3, 5 ) 
 
5 9 128 
(9.15.5, 2.8 ) 
- 14 
(9.15.3, 8 ) 
-b 
6 12 67 
(11.15.5, 4.1) 
- - - 
7 18 36 
(13.15.5, 5.1) 
- - - 
a) Relative Inhibitory Potency, calculated as (IC50)mono/IC50*valency ;  
b) Not measured, due to the low water solubility of 9.15.4 
 
